中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝癌合并门静脉高压的局部消融治疗

罗文 帖君

引用本文:
Citation:

肝癌合并门静脉高压的局部消融治疗

DOI: 10.3969/j.issn.1001-5256.2021.03.005
利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:罗文负责文献检索、撰写及修改论文;帖君负责拟定写作思路,指导撰写及修改论文,并最后定稿。
详细信息
    作者简介:

    罗文(1982—),女,副教授,博士,主要从事肝肿瘤超声造影诊断及超声引导下消融治疗

    通信作者:

    帖君,tiejun7776@163.com

  • 中图分类号: R735.7

Advances in local ablation therapy for liver cancer with portal hypertension

  • 摘要: 随着多种治疗方法的综合应用,原发性肝癌患者生存期不断延长。对于合并门静脉高压的早期肝癌患者,局部消融治疗可达到长期生存,并在稳定门静脉压力,保存肝脏功能,减少并发症等方面具有积极的作用。此外,局部消融可以和经肝动脉化疗栓塞术、经颈内静脉肝内门体分流术、脾切除、贲门周围血管离断术等方法相结合,进一步提高疗效。围手术期客观评价门静脉压力,预防食管胃底静脉曲张破裂出血,纠正脾功能亢进和防止术后肝衰竭,做好多学科团队协作管理,有助于提升消融后患者的管理效率。

     

  • 表  1  肝切除术和局部消融治疗合并门静脉高压的HCC患者效果比较

    第一作者及文献 年份 治疗方法 例数 肿瘤大小(cm) P1) 1、3、5年生存率 P1) 并发症发生率 P1)
    Xiao[8] 2015 肝切除术 58 80.4%、55.6%、28.1% 32.8%;1例因术后出血及肝衰竭死亡
    TACE/热消融 42 60.7%、24.4%、7.3% <0.001 26.2%;无死亡病例 >0.05
    Qiu[11] 2015 肝切除术 123 3.1±1.1 96.5%、74.9%、57.0% Clavien-Dindo分级
    Grade1~2:59.3%
    Grade3~5:6.5%
    热消融 57(微波),79(射频) 2.9±1.1 <0.05 91.8%、56.7%、41.1 % 0.01 Grade1~2:27.2%
    Grade3~5:2.2%
    <0.05
    Harada[12] 2016 肝切除术 20 2.1 (0.7~5)2) 100%、91%、91% Clavien-Dindo分级
    Grade1~2:30.9%
    Grade3~5:16.1%
    热消融 20(射频) 1.4 (0.7~2.4)2) <0.05 100%、91%、60% >0.05 Grade1~2:10%
    Grade3~5:2.5%
    <0.05
    Karabulut[13] 2012 肝切除术 923) 5.3(1.5~18)2) 5年:40% 32%
    热消融 92(射频)3) 3.1(1~7)2) <0.05 5年:21% <0.05 3% <0.05
    邹浩[14] 2018 肝切除 61 88.1%、64.1%、40.3%4)
    热消融 93 84.9%、52.8%、43.4%4) >0.05
    王鹤霖[15] 2017 肝切除 41 3.6±1.7 95%、74% 58.5%;Clavien-Dindo分级Ⅲ以上:7.3%
    热消融 48(微波) 2.40±0.95 <0.05 94%、80% >0.05 64.6%;Clavien-Dindo分级Ⅲ以上:0 >0.05
    注:1)消融组与肝切除组比较;2)中位数(范围);3)肝切除术组不合并门静脉高压,腹腔镜射频消融组中患者合并门静脉高压;4)1、3、5年无瘤生存率。
    下载: 导出CSV
  • [1] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.05.009

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.05.009
    [2] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019
    [3] OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370. DOI: 10.1007/s12072-017-9799-9
    [4] HERNANDEZ-GEA V, TURON F, BERZIGOTTI A, et al. Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension[J]. World J Gastroenterol, 2013, 19(8): 1193-1199. DOI: 10.3748/wjg.v19.i8.1193
    [5] BRUIX J, REIG M, SHERMAN M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853. DOI: 10.1053/j.gastro.2015.12.041
    [6] RUBINSTEIN MM, KAUBISCH A, KINKHABWALA M, et al. Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation[J]. J Gastrointest Oncol, 2017, 8(6): 1051-1055. DOI: 10.21037/jgo.2017.08.11
    [7] KAO WY, CHAO Y, CHANG CC, et al. Prognosis of early-stage hepatocellular carcinoma: The clinical implications of substages of Barcelona Clinic Liver Cancer System based on a cohort of 1265 patients[J]. Medicine (Baltimore), 2015, 94(43): e1929. DOI: 10.1097/MD.0000000000001929
    [8] XIAO H, ZHANG B, MEI B, et al. Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: A long-term benefit compared with transarterial chemoembolization and thermal ablation[J]. Medicine (Baltimore), 2015, 94(7): e495. DOI: 10.1097/MD.0000000000000495
    [9] MORISE Z. Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease[J]. Transl Gastroenterol Hepatol, 2018, 3: 41. DOI: 10.21037/tgh.2018.07.01
    [10] YOUNG S, GOLZARIAN J. Locoregional therapies in the treatment of 3- to 5-cm hepatocellular carcinoma: Critical review of the literature[J]. AJR Am J Roentgenol, 2020, 215(1): 223-234. DOI: 10.2214/AJR.19.22098
    [11] QIU J, ZHENG Y, SHEN J, et al. Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study[J]. Surgery, 2015, 158(5): 1235-1243. DOI: 10.1016/j.surg.2015.04.002
    [12] HARADA N, SHIRABE K, MAEDA T, et al. Comparison of the outcomes of patients with hepatocellular carcinoma and portal hypertension after liver resection versus radiofrequency ablation[J]. World J Surg, 2016, 40(7): 1709-1719. DOI: 10.1007/s00268-016-3465-6
    [13] KARABULUT K, AUCEJO F, AKYILDIZ HY, et al. Resection and radiofrequency ablation in the treatment of hepatocellular carcinoma: A single-center experience[J]. Surg Endosc, 2012, 26(4): 990-997. DOI: 10.1007/s00464-011-1983-8
    [14] ZOU H, WU LQ. A propensity score matching analysis of hepatectomy and radiofrequency ablation for patients with solitary hepatocellular carcinoma less than or equal to 5 cm and portal hypertension[J]. Chin J Dig Surg, 2018, 17(10): 1018-1023. (in Chinese)

    邹浩, 吴力群. 肝切除术与射频消融术治疗单发肿瘤直径≤5 cm肝细胞癌合并门静脉高压症患者的倾向评分匹配疗效分析[J]. 中华消化外科杂志, 2018, 17(10): 1018-1023.
    [15] WANG HL, DAI CL, ZHAO Y, et al. Comparison of liver resection vs. microwave ablation for patients with hepatocellular carcinoma and portal hypertension in early stage[J]. J Abdominal Surg, 2017, 30(2): 103-108. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-FBWK201702008.htm

    王鹤霖, 戴朝六, 赵阳, 等. 伴有门静脉高压症的早期肝癌病人肝切除与微波消融的疗效比较[J]. 腹部外科, 2017, 30(2): 103-108. https://www.cnki.com.cn/Article/CJFDTOTAL-FBWK201702008.htm
    [16] JIANG L, YAN L, WEN T, et al. Comparison of outcomes of hepatic resection and radiofrequency ablation for hepatocellular carcinoma patients with multifocal tumors meeting the Barcelona-Clinic Liver Cancer Stage A Classification[J]. J Am Coll Surg, 2015, 221(5): 951-961. DOI: 10.1016/j.jamcollsurg.2015.08.009
    [17] LEE S, JEONG WK, RHIM H. Repeated percutaneous radiofrequency ablation for hepatocellular carcinoma in patients with cirrhosis: Assessment of safety based on liver function and portal hypertension parameters[J]. J Vasc Interv Radiol, 2014, 25(10): 1573-1579. DOI: 10.1016/j.jvir.2014.06.015
    [18] KIM PN, CHOI D, RHIM H, et al. Planning ultrasound for percutaneous radiofrequency ablation to treat (< 3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: A multicenter prospective study to assess factors affecting ultrasound visibility[J]. J Vasc Interv Radiol, 2012, 23(5): 627-634. DOI: 10.1016/j.jvir.2011.12.026
    [19] SANTAMBROGIO R, BARABINO M, BRUNO S, et al. Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: A single European center experience of 426 patients[J]. Surg Endosc, 2016, 30(5): 2103-2113. DOI: 10.1007/s00464-015-4468-3
    [20] CILLO U, VITALE A, DUPUIS D, et al. Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: A cohort study[J]. PLoS One, 2013, 8(2): e57249. DOI: 10.1371/journal.pone.0057249
    [21] DÍAZ-GONZÁLEZ Á, VILANA R, BIANCHI L, et al. Thermal ablation for intrahepatic cholangiocarcinoma in cirrhosis: Safety and efficacy in non-surgical patients[J]. J Vasc Interv Radiol, 2020, 31(5): 710-719. DOI: 10.1016/j.jvir.2019.06.014
    [22] JIA Z, ZHANG K, JIANG L, et al. Simultaneous radiofrequency ablation combined with laparoscopic splenectomy: A safe and effective way for patients with hepatocellular carcinoma complicated with cirrhosis and hypersplenism[J]. Minim Invasive Ther Allied Technol, 2020, 29(3): 177-184. DOI: 10.1080/13645706.2019.1609990
    [23] PEI Y, CHAI S, ZHANG Y, et al. Benefits of splenectomy and curative treatments for patients with hepatocellular carcinoma and portal hypertension: A retrospective study[J]. J Gastrointest Surg, 2019, 23(11): 2151-2162. DOI: 10.1007/s11605-018-3981-9
    [24] CHENG J, WU WD, HU ZM, et al. Simultaneous microwave ablation therapy combined with laparoscopic splenectomy plus pericardial devascularization for the treatment of small hepatocellular carcinoma with portal hypertension[J]. Chin J Hepatobiliary Surg, 2019, 25(8): 622-624. (in Chinese) http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgdwk201908014

    成剑, 吴伟顶, 胡智明, 等. 微波消融联合腹腔镜脾切除加贲门周围血管离断术治疗小肝癌合并门静脉高压症[J]. 中华肝胆外科杂志, 2019, 25(8): 622-624. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgdwk201908014
    [25] ZHANG K, JIANG L, JIA Z, et al. Radiofrequency ablation plus devascularization is the preferred treatment of hepatocellular carcinoma with esophageal varices[J]. Dig Dis Sci, 2015, 60(5): 1490-1501. DOI: 10.1007/s10620-014-3455-1
    [26] HU K, LEI P, YAO Z, et al. Laparoscopic RFA with splenectomy for hepatocellular carcinoma[J]. World J Surg Oncol, 2016, 14(1): 196. DOI: 10.1186/s12957-016-0954-x
    [27] ZHENG L, LI HL, GUO CY, et al. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas[J]. Korean J Radiol, 2018, 19(2): 237-246. DOI: 10.3348/kjr.2018.19.2.237
    [28] SAVIANO A, IEZZI R, GIULIANTE F, et al. Liver resection versus radiofrequency ablation plus transcatheter arterial chemoembolization in cirrhotic patients with solitary large hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2017, 28(11): 1512-1519. DOI: 10.1016/j.jvir.2017.06.016
    [29] BOSCH J, ABRALDES JG, BERZIGOTTI A, et al. The clinical use of HVPG measurements in chronic liver disease[J]. Nat Rev Gastroenterol Hepatol, 2009, 6(10): 573-582. DOI: 10.1038/nrgastro.2009.149
    [30] YANG W, YAN K, GOLDBERG SN, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment[J]. World J Gastroenterol, 2016, 22(10): 2993-3005. DOI: 10.3748/wjg.v22.i10.2993
    [31] WANG K, LIU G, LI J, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: A prospective cohort study[J]. Eur J Surg Oncol, 2015, 41(2): 236-242. DOI: 10.1016/j.ejso.2014.11.002
    [32] WU WC, CHIOU YY, HUNG HH, et al. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation[J]. J Clin Gastroenterol, 2012, 46(9): 789-795. DOI: 10.1097/MCG.0b013e31825ceeb5
    [33] ARIO K, MIZUTA T, EGUCHI Y, et al. Presence of esophageal varices is a risk factor for non-hemorrhagic death of hepatocellular carcinoma patients treated with radiofrequency ablation[J]. Hepatogastroenterology, 2010, 57(99-100): 501-506. http://new.med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_JJ0216294688
    [34] KIM R, JEONG WK, KANG TW, et al. Intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma: relationship with portal hypertension[J]. Acta Radiol, 2019, 60(12): 1609-1618. DOI: 10.1177/0284185119842830
    [35] FANG KC, SU CW, CHIOU YY, et al. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: A propensity score matching analysis[J]. Eur Radiol, 2017, 27(6): 2600-2609. DOI: 10.1007/s00330-016-4604-z
    [36] LLOVET JM, BRU C, BRUIX J. Prognosis of hepatocellular carcinoma: The BCLC staging classification[J]. Semin Liver Dis, 1999, 19: 329-338. DOI: 10.1055/s-2007-1007122
    [37] BERZIGOTTI A. Non-invasive evaluation of portal hypertension using ultrasound elastography[J]. J Hepatol, 2017, 67(2): 399-411. DOI: 10.1016/j.jhep.2017.02.003
    [38] BERZIGOTTI A, SEIJO S, ARENA U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis[J]. Gastroenterology, 2013, 144(1): 102-111. e1. DOI: 10.1053/j.gastro.2012.10.001
    [39] EL SHERBINY W, ABDELRAHMAN A, DIASTY M, et al. Changes in Doppler parameters of portal pressure after interventional management of hepatocellular carcinoma[J]. Abdominal radiology, 2016, 41(8): 1532-1538. DOI: 10.1007/s00261-016-0704-0
    [40] KIM H, CHOI D, LEE JH, et al. High-risk esophageal varices in patients treated with locoregional therapy for hepatocellular carcinoma: Assessment with liver computed tomography[J]. World J Gastroenterol, 2012, 18(35): 4905-4911. DOI: 10.3748/wjg.v18.i35.4905
    [41] QIU B, ZHAO MF, YUE ZD, et al. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension[J]. World J Gastroenterol, 2015, 21(43): 12439-12447. DOI: 10.3748/wjg.v21.i43.12439
    [42] PARK JK, AL-TARIQ QZ, ZAW TM, et al. Radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts[J]. Cardiovasc Intervent Radiol, 2015, 38(5): 1211-1217. DOI: 10.1007/s00270-015-1050-2
    [43] SONOMURA T, KAWAI N, KISHI K, et al. N-butyl cyanoacrylate embolization with blood flow control of an arterioportal shunt that developed after radiofrequency ablation of hepatocellular carcinoma[J]. Korean J Radiol, 2014, 15(2): 250-253. DOI: 10.3348/kjr.2014.15.2.250
    [44] WU TT, LI HC, ZHENG F, et al. Percutaneous endovascular radiofrequency ablation for malignant portal obstruction: An initial clinical experience[J]. Cardiovasc Intervent Radiol, 2016, 39(7): 994-1000. DOI: 10.1007/s00270-016-1317-2
    [45] GABA RC, KALLWITZ ER, PARVINIAN A, et al. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients[J]. Ann Hepatol, 2013, 12(5): 766-773. DOI: 10.1016/S1665-2681(19)31318-3
  • 加载中
表(1)
计量
  • 文章访问数:  516
  • HTML全文浏览量:  109
  • PDF下载量:  71
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-08
  • 录用日期:  2020-12-16
  • 出版日期:  2021-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回